Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TRPV1 | Q8NER1 | 14/20 | 0.53 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.49 |
| ▸ | HTR2C | P28335 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 2/20 | 0.43 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.43 |
| ▸ | PPARA | Q07869 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4338606 | 1.00 | TRPV1 (0.53) | TRPV1OPRM1HTR2CNAMPTEPHX2 | |
| SCHEMBL4333843 | 1.00 | TRPV1 (0.53) | TRPV1OPRM1HTR2CNAMPTEPHX2 | |
| SCHEMBL2734364 | 0.97 | TRPV1 (0.51) | TRPV1OPRM1HTR2CNAMPTEPHX2 | |
| SCHEMBL2734543 | 0.91 | TRPV1 (0.49) | TRPV1OPRM1EPHX2PPARA | |
| SCHEMBL4340575 | 0.90 | TRPV1 (0.54) | TRPV1OPRM1EPHX2 | |
| SCHEMBL13613648 | 0.90 | TRPV1 (0.52) | TRPV1OPRM1NAMPT | |
| SCHEMBL2734517 | 0.90 | TRPV1 (0.48) | TRPV1OPRM1NAMPT | |
| SCHEMBL12460097 | 0.88 | TRPV1 (0.42) | TRPV1OPRM1HTR2CNAMPT | |
| SCHEMBL2733683 | 0.88 | TRPV1 (0.49) | TRPV1OPRM1NAMPT | |
| SCHEMBL4341559 | 0.87 | TRPV1 (0.59) | TRPV1OPRM1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | claimed |
| EP-1506167-B1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-08-29 | — | — | EP | claimed |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | BAYER HEAITHCARE AG (DE) | 2006-11-16 | — | — | US | claimed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| US-7612113-B2 | Such as N-[4-chloro-3-(trifluoromethyl)phenyl]-N'-(7-hydroxy-5,6,7,8-tetrahydro-1-naphthalenyl)urea; vanilloid receptor antagonists; for treatment of urge urinary incontinence, overactive bladder, chronic pain, neuropathic pain, postoperative pain, rheumatoid arthritic pain, neuralgia, neuropathies, COPD | XENTION LIMITED (GB) | 2009-11-03 | — | — | US | disclosed |
| EP-1893189-A2 | USE OF HYDROXY TETRAHYDRO-NAPHTHALENE DERIVATIVES FOR THE TREATMENT OF RESPIRATORY DISEASES | Bayer HealthCare AG (DE) | 2008-03-05 | — | — | EP | disclosed |
| EP-1506167-B1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2007-08-29 | — | — | EP | disclosed |
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | BAYER HEAITHCARE AG (DE) | 2006-11-16 | — | — | US | disclosed |
| WO-2006094627-A2 | USE OF HYDROXY TETRAHYDRO-NAPHTALENE DERIVATES FOR THE TREATMENT OF RESPIRATORY DISEASES | BAYER HEALTHCARE AG (DE) | 2006-09-14 | — | — | WO | disclosed |
| EP-1506167-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | Bayer HealthCare AG (DE) | 2005-02-16 | — | — | EP | disclosed |
| WO-2005002551-A2 | VANILLOID RECEPTOR (VR) 1 INHIBITORS FOR TREATMENT OF HUMAN IMMUNODEFICIENCY VIRUS (HIV)-MEDIATED PAIN STATES | BAYER HEALTHCARE AG (DE) | 2005-01-13 | — | — | WO | disclosed |
| EP-1493438-A1 | Vanilloid receptor (VR) inhibitors for treatment of Human Immunodeficiency Virus (HIV)-mediated pain states | Bayer HealthCare AG (DE) | 2005-01-05 | — | — | EP | disclosed |
| WO-2003095420-A1 | HYDROXY TETRAHYDRO-NAPHTHALENYLUREA DERIVATIVES | BAYER HEALTHCARE AG (DE) | 2003-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060258742-A1 | Hydroxy tetrahydro-naphthalenylurea derivatives | NMUR1, HVCN1, GPR17 | TRPV1 18/4885OPRM1 168/4885HTR2C 491/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.